Thursday 16 October, 2025
Objectives: Bintrafusp alfa (BA) is a first-in-class bifunctional fusion protein targeting transforming growth factor-β and programmed death-ligand 1. This analysis…
Read moreAbstracts
Comparison between multistate and parametric time-to-event models for analysis of progression-free-survival (PFS) and overall survival (OS) in oncology trials
Thursday 16 October, 2025
Objectives: In oncology settings, survival analysis is often conducted to assess the relationship between predictors and efficacy endpoints like progression-free survival…
Read moreMake models great again by optimally restricting parameters to make non-identifiable models provably identifiable
Thursday 16 October, 2025
Objectives: One of the goals of statistical learning is to identify the underlying parameter values in a parametric model that…
Read moreFast cross-validation for Bayesian inference using proposals on a linear subspace
Thursday 16 October, 2025
Objectives: Hierarchical models typically found in the field of pharmacometrics have a number of parameters that scales with the number…
Read morePopulation pharmacokinetic modeling of lisinopril at steady-state in hypertensive pediatric patients with mild to moderate renal impairment
Thursday 16 October, 2025
Objectives: Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is the most frequently prescribed antihypertensive therapeutic in the pediatric population, indicated primarily in…
Read moreApplication of Physiologically Based Pharmacokinetic Modeling and Population Pharmacokinetic Modeling to predict potential Drug-Drug Interaction (DDI) between rivaroxaban and carbamazepine.
Thursday 16 October, 2025
Objectives: Rivaroxaban (direct oral anticoagulants, CYP3A4 substrate drug) and carbamazepine (anti-epileptic drug, potent CYP3A4 inducer) could be prescribed concomitantly to…
Read morePrediction of potential drug-drug interaction of tofacitinib and ritonavir using a population modeling approach with allometric scaling method
Thursday 16 October, 2025
Objectives: Tofacitinib (TOF) is a small molecule Janus kinase (JAK) inhibitor that is used in the treatment of rheumatoid arthritis…
Read moreOn the influence of sampling schemes on the demonstration of bioequivalence
Thursday 16 October, 2025
Objectives: Bioequivalence (BE) studies compare the concentration-time (C-t) profiles of two pharmaceutical products (test (T) and reference (R)) of the same…
Read moreAdaptive therapy: Leveraging eco-evolutionary principles to improve resistance management in oncology
Thursday 16 October, 2025
Introduction/Objectives: Improving the management of drug resistance is a key challenge in modern oncology. Currently, this problem is approached by…
Read morePharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients
Thursday 16 October, 2025
Introduction: Brigatinib is a recently approved drug for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC)….
Read more